The emergence of two new cases of mpox (formerly known as monkeypox) in the United Kingdom has sent ripples of concern through public health officials and the general public alike.
As of October 2024, the UK is witnessing a resurgence of mpox cases, with the latest report confirming two infections that are presumed to have been contracted within the country, rather than imported from endemic regions.
This marks a significant development in the ongoing outbreak that began in May 2022. Data from the UK Health Security Agency (UKHSA) reveals that since the outbreak’s inception, there have been approximately 4,100 confirmed and highly probable mpox cases in the UK, with 3,899 of these reported in England.
In 2023 and 2024 alone, England recorded 368 cases, with 159 presumed to have been acquired domestically. The recent cases have raised alarms about the potential for renewed community transmission, particularly among populations identified as high-risk.
Mpox is a zoonotic viral infection caused by the monkeypox virus (MPXV), primarily found in Central and West Africa. Initially identified in laboratory monkeys in 1958, it has since been recognized as a significant public health concern affecting humans, particularly in the context of the recent outbreak that began in 2022.
The transmission dynamics of mpox indicate that it spreads through direct contact with infected individuals or contaminated materials, and respiratory droplets during prolonged face-to-face interactions can also facilitate its spread. While the outbreak has predominantly affected gay, bisexual, and other men who have sex with men (MSM), it is crucial to acknowledge that anyone can contract mpox, regardless of sexual orientation.
In response to the resurgence of mpox, the UK government and health authorities have implemented a series of measures aimed at controlling its spread. Vaccination campaigns have ramped up, with the UK making vaccines such as JYNNEOS (also known as Imvamune or Imvanex) available.
These vaccines are prioritized for high-risk groups, including close contacts of confirmed cases and individuals with potential exposure. Enhanced surveillance systems have been established to monitor mpox cases actively, with refined testing protocols using polymerase chain reaction (PCR) tests to ensure rapid identification of suspected cases. Public health authorities are also conducting contact tracing to identify individuals who may have been exposed to confirmed cases.
Join our Channel...